Alpha-lipoic acid treatment in type 2 diabetes patients with diabetic polyneuropathy

• Gorshkov I.P.
• Volynkina A.P.

AbstractClinical and laboratory efficacy of α-lipoic acid (ALA) in type 2 diabetes mellitus (DM2) patients with diabetic polyneuropathy (DPN) was evaluated. There were 59 DM2 patients with DPN under observation: 27 (45.8%) women and 32 (54.2%) men. 30 patients were additionally treated with iv 600 mg of ALA daily for 14 days. Total serum oxidative capacity and level of IgG antibodies to oxidized low-density lipoprotein (MDA-LDLc IgG) decreased by 13.9% (Δ-0.5) and 12.9% (Δ-45.8) respectively in ALA-treated group compared with control group and total serum antioxidant capacity increased by 27.3% (Δ+ 29.4) (U, p <0.05), which affected DPN subjective and objective manifestations: TSS index is lower by 11.6% (Δ-1.1), NDS by 9.1% (δ-1.5), DN4 by 14.3% (Δ-0.9) (U, p<0.05).

Keywords:diabetes mellitus, diabetic polyneuropathy, alpha-lipoic acid, oxidative stress

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)